2 pharma stocks that could make you a millionaire

The FTSE 100 isn’t the last word for great pharmaceutical stocks. Here, Royston Wild looks at two medical marvels outside of the blue-chip index.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

While GlaxoSmithKline and AstraZeneca may be the first port of call for many investors looking to get a foothold in the pharmaceuticals sector, they are by no means the only hot stocks expected to deliver blockbuster earnings expansion in the years ahead.

Indeed, there are a broad range of medicine producers tipped to produce brilliant returns this year and beyond. And in this article I am looking at two of these pharma fizzers: BTG (LSE: BTG) and Dechra Pharmaceuticals (LSE: DPH).

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

The right treatment

BTG’s latest trading statement this month reinforced my optimistic take further, the company noting that “there is good momentum across the business with significant progress achieved during the [half-year] period.”

The business saw product sales at constant currencies rise by double-digit percentages during April-September, meaning that full-year sales targets remain in sight. Revenues at its Specialty Pharmaceuticals division are expected to swell by low-to-mid single digits at stable exchange rates, BTG advised, while sales at Interventional Medicine should rise in the mid-to-high teens.

This was not the only positive news BTG furnished the market with last week. Indeed, the company announced that its aggressive M&A drive has seen it acquire US-based Roxwood Medical — which provides cardiovascular speciality catheters for use in patients with heart trouble — for a fee which could eventually rise to $80m. Revenues at Roxwood should balloon in the years ahead and provide synergetic benefits to BTG’s existing operations in this area.

BTG has seen earnings rattle steadily higher in recent years, and City brokers are expecting meaty growth of 27% in the year ending March 2018. An additional 14% advance is pencilled in for fiscal 2019 too.

And these projections make the FTSE 250 star excellent value too. Sure, a forward P/E ratio of 24.1 times may sit well outside the widely-considered value watermark of 15 times. However, a corresponding PEG reading of 0.9 suggests BTG is actually brilliantly priced relative to its growth potential.

Animal spirits

Animalcare specialist Dechra Pharmaceuticals (LSE: DPH) is another pharma share expected to deliver stonking profits growth in the nearterm and beyond.

Like BTG, the Cheshire-based entity has a long history of annual earnings rises behind it. And City analysts are not expecting this impressive run to end just yet, a chunky 13% rise being forecast for the 12 months ending June 2018.

Dechra has also been hot on the M&A trail in recent years to bolster its already impressive product pipeline and expand its geographical footprint, a strategy which keeps blasting revenues skywards (at constant currencies sales increased 28.3% during the 12 months to June, to £359.3m).

Rampant share picker demand has seen Dechra’s share price head for the clouds in recent months, the business gaining 60% in value since the turn of 2017. While this also leaves the business dealing on a conventionally-high forward P/E ratio of 29.4 times, I believe this is fair value given that medicines demand for domestic and agricultural animals should continue climbing at a stratospheric rate.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca and BTG. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Senior woman wearing glasses using laptop at home
Investing Articles

SSE shares are up 15% since the market correction! Should I buy?

Jabran Khan looks at why SSE shares have been on an upward trajectory in recent weeks and decides if he…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

After crashing 29%, Spectris shares look cheap to me

After peaking at 4,167p last September, Spectris shares have slumped by over 29%. But I see deep value in the…

Read more »

British Pennies on a Pound Note
Investing Articles

Here is why I added this dirt-cheap FTSE 100 penny stock to my holdings!

Jabran Khan explains why he added this dirt-cheap FTSE 100 stock to his holdings and is excited by its recovery…

Read more »

Woman looking at a jar of pennies
Investing Articles

3 FTSE 100 penny stocks! Which is the cheapest buy?

Our writer examines three penny stocks that feature in the FTSE 100 index to ascertain whether they have a place…

Read more »

Arrowings ascending on a chalkboard
Investing Articles

Is the Vodafone share price an opportunity at current levels?

Jabran Khan looks at the current Vodafone share price and decides if he would add the shares to his holdings…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

4 gems I’d include in my Stocks & Shares ISA

Jon Smith explains some of the top stocks he's thinking about including in his Stocks and Shares ISA a we…

Read more »

Compass pointing towards 'best price'
Investing Articles

At 85p, are Rolls-Royce shares a no-brainer buy? 

The Rolls-Royce share price look very cheap right now. And I think this might be my last chance to buy…

Read more »

positive mental health woman
Investing Articles

My £3-a-day blue-chip passive income plan

Our writer sets out his passive income plan of investing a few pounds each day in top stocks.

Read more »